Compare APPS & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APPS | KARD |
|---|---|---|
| Founded | N/A | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2012 | 2026 |
| Metric | APPS | KARD |
|---|---|---|
| Price | $10.50 | $12.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $17.00 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 2.5M | 618.2K |
| Earning Date | 11-02-2026 | 11-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,569,000.00 | N/A |
| Revenue This Year | $17.68 | N/A |
| Revenue Next Year | $11.78 | $50.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.55 | N/A |
| 52 Week Low | $2.74 | $12.23 |
| 52 Week High | $15.34 | $27.00 |
| Indicator | APPS | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 36.47 |
| Support Level | $10.07 | $12.23 |
| Resistance Level | $10.80 | $15.93 |
| Average True Range (ATR) | 0.68 | 1.38 |
| MACD | -0.07 | 0.09 |
| Stochastic Oscillator | 54.71 | 18.92 |
Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.